Every year millions of cancer patients could be saved from prema­ture death and suffering if they had timely access to early detection and treatment.

World Health Organization

Onco­Lab Diag­nos­tics aims to contribute sub­stan­tially to enhanc­ing sur­vival time and qual­ity of life of can­cer patients and reduc­ing can­cer mor­tal­ity. We will achive this by devel­op­ing, man­u­fac­tur­ing and mar­ket­ing highly inno­v­a­tive and utmost pre­cise can­cer tests.

To achieve our goals we engage in research and devel­op­ment activ­i­ties in close coop­er­a­tion with renowned world­wide acad­e­mia and indus­try part­ners. Onco­lab Diag­nos­tics is ded­i­cated to research and devel­op­ment to find new means and tech­nolo­gies to diag­nose can­cer and to characterise its specific nature.


Treatment alone will not win the war on cancer: prevention and early detection are crucial.

 WHO World Cancer Report 2014


Despite legions of researchers trying to find appropriate diag­nostic and curative measures, overall cancer mortality could not be reduced for decades. Cur­rently, there is an urgent need for reliable non-invasive diagnostic tools.


OncoLab Diagnostics combines its profound expertise in the field of cancer research with the ambition to improve the lives and outlook for cancer patients


Liq­uid Biopsy
Circulating Tumour Cells

A new age of per­son­al­ized can­cer care begun with the intro­duc­tion of “Liq­uid Biopsy”, a blood test detect­ing can­cer in the cir­cu­la­tion and pro­vid­ing a non-​invasive pic­ture of a patient’s can­cer. It offers pos­si­ble post-​therapeutic sur­veil­lance of recurrence.

Blood biopsy diag­nos­tics is a mix of high-​tech tech­nol­ogy and cut­ting edge med­ical pro­ce­dures, and offers new ways for selec­tion of the right drug for the right patient at the right time — all through a sim­ple blood draw.

Blood-Based Testing
Immune Signature

Just a blood sam­ple is needed to see whether a per­son suf­fers from can­cer or not. Also the infor­ma­tion if a can­cer patient is respond­ing to a cer­tain ther­apy or if an alter­na­tive treat­ment should be cho­sen, can been derived from a sin­gle blood sample.


Liquid Biopsy Tests

The tests allow doctors to choose the most effi­cient treat­ment for their cancer patients. In addition, the tests will be designed to detect ther­apy fail­ures and/or can­cer recur­rence at an early statge which allows re-defining and adjusting the therapy in a timely manner.
The tests will be used to assess in real time whether the current therapy is effective or not. They will be applied at dif­fer­ent time points, namely before, dur­ing and after the ther­apy. When used in follow-​up sur­veil­lance after com­ple­tion of a  ther­apy, the monitoring tests even enable early detec­tion of a possible can­cer relapse.
Due to their non-​invasive nature and easy applic­a­bil­ity these blood tests rep­re­sent so-called LIQ­UID BIOP­SIES which— unlike tis­sue biop­sies — can the­o­ret­i­cally be per­formed an unlim­ited num­ber of times.

Early Detec­tion of Cancer Tests

The early detection tests are applied to indi­vid­u­als who have a high risk to develop can­cer, e.g., due to a fam­ily his­tory or genetic pre­dis­po­si­tion.

Due to their out­stand­ing diag­nos­tic pre­ci­sion, these tests have high poten­tial to be used for population-​wide screen­ing in the long ​term.


The OncoLab team combines profound knowledge and expertise in tumour biology, oncology and international research projects. Besides the high scientific quality, the CEO of OncoLab has long-term experience in managing and operating diagnostics enterprises as well as in developing and marketing diagnostic tests.

Contact us

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Straße 2, Objekt E
2700 Wiener Neustadt

Phone: +43 (0)2622 / 32913

Please enter your name.
Please enter a message.

© OncoLab Diagnostics GmbH 2019

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Str. 2, Bldg. E
2700 Wiener Neustadt